Uzbekinvest Acquires Risk and Capital Modelling Capabilities From Ultimate Risk Solutions Which Helped Them Attain Stable AM Best Rating
31.7.2024 15:00:00 EEST | Business Wire | Press release
Ultimate Risk Solutions (“URS”) is proud to announce its important contribution into assisting Uzbekinvest Export-Import Insurance Company of Uzbekistan (“Uzbekinvest”) in attaining their stable AM Best credit rating. Through the development of advanced risk models of Uzbekinvest’s insurance and reinsurance lines of business, including catastrophe risk, URS has contributed significantly to this achievement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730430996/en/
Uzbekinvest acquires risk and capital modelling capabilities from Ultimate Risk Solutions (URS) which helped them attain stable AM Best rating (Graphic: Business Wire)
AM Best, a global credit rating agency specializing in the insurance industry, has revised the outlook for Uzbekinvest from negative to stable. The Financial Strength Rating remains at B (Fair), and the Long-Term Issuer Credit Rating at “bb” (Fair). This positive shift reflects Uzbekinvest’s enhanced risk-adjusted capitalization, in part attributed to the sophisticated risk modelling and probable maximum loss estimation facilitated by URS.
URS’s expertise in risk analysis and modelling has been instrumental in this process, showcasing the company’s commitment to delivering tailored risk solutions that enhance the financial stability and performance of its clients.
“Our company, which is the largest insurance and reinsurance provider in Uzbekistan, has made significant advances in the international markets, and is striving to become a global player closely working with AM Best during the process. Risk and capital modelling capabilities offered by URS technologies allow us to keep an eye on the solvency and stability of our global risk portfolio as it continues to grow,” said Rustam Azimov, General Director of Uzbekinvest.
“We are delighted to have supported Uzbekinvest in their journey towards improved financial strength and stability,” said Alex Bushel, Founder and CEO at Ultimate Risk Solutions. “Our team’s dedication to developing sophisticated and comprehensive risk models underscores our mission to empower our clients with the tools necessary for effective risk management and sustainable growth.”
This collaboration marks a significant milestone for both Uzbekinvest and URS, highlighting the importance of innovative risk management strategies in the insurance sector. As URS continues to pioneer in risk modelling and analysis, it remains committed to helping its clients navigate the complexities of risk with confidence and precision.
About Uzbekinvest:
Uzbekinvest Export-Import Insurance Company JSC is a prominent insurance and reinsurance provider in Uzbekistan and globally. The company is committed to offering reliable and comprehensive insurance and reinsurance solutions to its clients, backed by leading modern technologies and a team of dedicated professionals. This company manages total assets valued at USD 164 million and maintains substantial reserves amounting more than USD 106 million, indicating strong financial stability and capacity to cover potential liabilities. Uzbekinvest boasts a robust global footprint, handling risks from 132 countries. It maintains strong partnerships with major reinsurance companies such as Munich Re, Swiss Re, Allianz, Zurich Insurance Company and collaborates with top-tier broking firms including AON, Willis, Marsh, Guy Carpenter, Howden and others to enhance its market reach and service capabilities.
About Ultimate Risk Solutions:
Ultimate Risk Solutions (URS) is a leading provider of risk modelling and analysis technologies and services, offering advanced solutions for insurance companies and financial institutions globally. With a focus on innovation and precision, URS delivers technologies that help clients enhance their risk management practices and achieve their strategic objectives.
Link to AM Best press release regarding revised Uzbekinvest rating outlook:
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730430996/en/
Contacts
Sasha Kuznetsov, URS Marketing and Communications Lead | akuznetsov@ultirisk.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Technology Innovation Institute Completes Asteroid-Landing Probe for Landmark Emirates Mission to the Asteroid Belt5.10.2026 10:42:00 EEST | Press release
The Technology Innovation Institute (TII) has revealed the UAE-built probe it has developed for the Emirates Mission to the Asteroid Belt (EMA). The probe will soon travel to Colorado, USA, for final integration with the MBR Explorer spacecraft ahead of its planned 2028 launch. In a historic first, TII’s probe will image two planets and seven asteroids — flying past six asteroids in the main belt before culminating in a rendezvous with and landing on the seventh, 269 Justitia. If successful, the landing will make Justitia only the seventh asteroid in history to be reached on the surface by the probe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261006586478/en/ H.E. Faisal Al Bannai, Secretary General of the Advanced Technology Research Council (ATRC), and H.E. Belhoul Al Falasi, Chairman of the UAE Space Agency, sign a model of the UAE-built probe developed by the Technology Innovation Institute (TII) for the Emirates Mis
JEOL: Sales launch of HAXIS: The New Low-angle Ion Milling Scanning Electron Microscope5.10.2026 10:30:00 EEST | Press release
JEOL Ltd. (President & CEO Izumi Oi) announces the development of its new low‑angle ion‑milling scanning electron microscope, HAXIS, and will commence sales on October 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928207899/en/ HAXIS Low-angle Ion Milling Scanning Electron Microscope HAXIS Low-angle Ion Milling Scanning Electron Microscope Background of development As advanced semiconductor device structures continue to shrink and grow more complex, it has become difficult to contact and measure microscale circuits using nano-manipulators. In addition, contact caused by probing may affect the analysis target, necessitating new failure analysis methods. JEOL has conducted long-term research on the passive voltage contrast (PVC) detection technology and established a method for stable, highly reproducible PVC observation technology through the advancement of detectors and sample preparation techniques. HAXIS is JE
Slate Asset Management and OneIM Agree to Acquire Portfolio of Grocery-Anchored Essential Real Estate in the Greater Oslo Region Valued at Approximately €250 Million5.10.2026 09:30:00 EEST | Press release
Slate Asset Management ("Slate"), a global investor and manager focused on essential real estate and infrastructure assets, and One Investment Management (“OneIM”), a global alternative investment manager, today announced they have agreed to acquire a portfolio of eight grocery-anchored retail parks in Norway from Tellus Eiendom AS. The portfolio is located in the Greater Oslo region and is anchored by Norway's leading grocery operators and discount retailers. “We are pleased to be expanding our European Essential real estate platform with this significant acquisition,” said Brady Welch, Co-Founding Partner of Slate Asset Management. “These eight retail parks sit in dominant locations along major transport corridors around Oslo. The portfolio is anchored by Norway's strongest grocery operators and benefits from CPI-linked lease structures, designed to provide durable, inflation-protected cash flows. We look forward to applying our active management to unlock the portfolio’s full potent
Bial Showcases Parkinson’s Research at MDS 20265.10.2026 09:00:00 EEST | Press release
Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, is presenting 16 scientific posters at the International Congress of Parkinson’s Disease and Movement Disorders (MDS 2026), taking place in Seoul, Korea, from 4 to 8 October. Reflecting Bial’s commitment to listening to and learning directly from people living with Parkinson’s, two presentations cover research initiatives focused on understanding their experiences, perspectives, and priorities. The first is the Patient Endpoint Preference Project (PEPP), an ongoing multinational observational study that seeks to identify and prioritise the symptoms and outcomes that matter most to people living with Parkinson’s. The second is the TRACK-PD study, which provides insights into treatment routines and adherence behaviours, contributing to a better understanding of the challenges experienced in real-world settings. These findings may support the integration of the perspectives of people living wi
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom